REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/12/2026
Back to search
Official data from USPTO
DARNITSA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
01/13/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
06/11/2019
Registration date
01/12/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/12/2021
Last transaction
01/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
UA
Examiner
BUONGIORNO,CHRISTOPHER L
Law office
L20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "DARNITSA".
Holders and representatives
Holders
PRIVATE JOINT STOCK COMPANY "PHARMACEUTICAL FIRM "DARNITSA"
Z. V. (pessoa física)
Representatives
Kenneth Motolenich-Salas Hickman Becker Bingham Ledesma LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antiseptics; vaccines; veterinary preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Vitamin preparations; disinfectants; diagnostic preparations for veterinary purposes; diagnostic preparations for medical purposes; dietetic beverages adapted for medical purposes; Dietetic foods and beverages adapted for medical use; dietetic foods adapted for medical purposes; plant extracts for pharmaceutical purposes; herbal extracts for medical purposes; Capsules sold empty for pharmaceuticals; medicinal preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Drugs for medical purposes for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Medicinal drinks; medicinal oils; medicated toiletry preparations; medicated shampoos; ointments for pharmaceutical purposesmedicated ointments for treating dermatological conditions and antibiotic ointments; teeth filling material; medicinal alcohol; food supplements; medical dressings; nutritional supplements; Pre-filled syringes containing pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Air purifying preparations; food for babies; protein dietary supplements; Tissues impregnated with pharmaceutical lotions for treating dermatological conditions; Alcohol for pharmaceutical purposes; stem cells for medical purposes; transplantssurgical implants comprising living tissue used in transplant operations; pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; ferments for pharmaceutical purposes; phytotherapy preparations for medical purposes; chemico-pharmaceutical preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Chemical preparations for medical purposes for the diagnosis of pregnancy; Chemical preparations for pharmaceutical purposes for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Chemical reagents for medical or veterinary purposes; surgical glues; surgical dressings; candymedicated; candy for medical purposes; sanitary preparations for medical purposes; plasters for medical purposes
Publications
History of USPTO decisions and trademark events.
38 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/28/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
08/03/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/03/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/03/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/03/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/30/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
04/13/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
04/13/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/12/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
01/12/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/18/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/27/2020
PUBO
PUBLISHED FOR OPPOSITION
10/27/2020
GPNX
NOTIFICATION PROCESSED BY IB
10/25/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/07/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
10/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/21/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
09/21/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/21/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
09/21/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/21/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/03/2020
ALIE
ASSIGNED TO LIE
09/03/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/13/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/12/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/12/2020
RFNT
REFUSAL PROCESSED BY IB
02/28/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/13/2020
RFRR
REFUSAL PROCESSED BY MPU
02/13/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/14/2020
MAFR
APPLICATION FILING RECEIPT MAILED
01/14/2020
CNRT
NON-FINAL ACTION WRITTEN
01/13/2020
DOCK
ASSIGNED TO EXAMINER
01/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/09/2020
Continuous trademark protection
Get notified about every new filing that threatens DARNITSA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.